{"id":7951,"date":"2011-11-05T20:33:28","date_gmt":"2011-11-05T20:33:28","guid":{"rendered":"https:\/\/drugprevent.org.uk\/ppp\/?p=7951"},"modified":"2016-10-04T15:54:58","modified_gmt":"2016-10-04T15:54:58","slug":"impact-of-cannabis-use-on-thalamic-volume-in-people-at-familial-high-risk-of-schizophrenia","status":"publish","type":"post","link":"https:\/\/drugprevent.org.uk\/ppp\/2011\/11\/impact-of-cannabis-use-on-thalamic-volume-in-people-at-familial-high-risk-of-schizophrenia\/","title":{"rendered":"Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia"},"content":{"rendered":"<p><span style=\"color: #0000ff;\"><strong>1.\u00a0Killian A. Welch, MD, MRCPsych\u00a0 et al\u00a0<\/strong><\/span><\/p>\n<p><span style=\"color: #0000ff;\">Correspondence:: <a style=\"color: #0000ff;\" href=\"mailto:kwelch1@staffmail.ed.ac.uk\">kwelch1@staffmail.ed.ac.uk<\/a><\/span><\/p>\n<p><span style=\"color: #0000ff;\"><strong>Background<\/strong><\/span><br \/>\n<span style=\"color: #0000ff;\"> No longitudinal study has yet examined the association between substance use and brain volume changes in a population at high risk of schizophrenia.<\/span><\/p>\n<p><span style=\"color: #0000ff;\"><strong>Aims<\/strong><\/span><br \/>\n<span style=\"color: #0000ff;\"> To examine the effects of cannabis on longitudinal thalamus and amygdala-hippocampal complex volumes within a population at high risk of schizophrenia.<\/span><\/p>\n<p><span style=\"color: #0000ff;\"><strong>Method<\/strong><\/span><br \/>\n<span style=\"color: #0000ff;\"> Magnetic resonance imaging scans were obtained from individuals at high genetic risk of schizophrenia at the point of entry to the Edinburgh High-Risk Study (EHRS) and approximately 2 years later. Differential thalamic and amygdala-hippocampal complex volume change in high-risk individuals exposed (n = 25) and not exposed (n = 32) to cannabis in the intervening period was investigated using repeated-measures analysis of variance.<\/span><\/p>\n<p><span style=\"color: #0000ff;\"><strong>Results<\/strong><\/span><br \/>\n<span style=\"color: #0000ff;\"> Cannabis exposure was associated with bilateral thalamic volume loss. This effect was significant on the left (F = 4.47, P = 0.04) and highly significant on the right (F = 7.66, P = 0.008). These results remained significant when individuals using other illicit drugs were removed from the analysis.<\/span><\/p>\n<p><span style=\"color: #0000ff;\"><strong>Conclusions<\/strong><\/span><br \/>\n<span style=\"color: #0000ff;\"> These are the first longitudinal data to demonstrate an association between thalamic volume loss and exposure to cannabis in currently unaffected people at familial high risk of developing schizophrenia. This observation may be important in understanding the link between cannabis exposure and the subsequent development of schizophrenia.<\/span><\/p>\n<p><span style=\"color: #0000ff;\">Source:\u00a0 bjp.rcpsych.org\u00a0\u00a0 Sept.2011<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>1.\u00a0Killian A. Welch, MD, MRCPsych\u00a0 et al\u00a0 Correspondence:: kwelch1@staffmail.ed.ac.uk Background No longitudinal study has yet examined the association between substance use and brain volume changes in a population at high risk of schizophrenia. Aims To examine the effects of cannabis on longitudinal thalamus and amygdala-hippocampal complex volumes within a population at high risk of schizophrenia. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[63,30],"tags":[],"class_list":["post-7951","post","type-post","status-publish","format-standard","hentry","category-brain-and-behaviour","category-cannabis-marijuana"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/7951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=7951"}],"version-history":[{"count":0,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/7951\/revisions"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=7951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=7951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=7951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}